EUVIMEDEUVIMED entdecken
Crossref

Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium

Priya Kumar, Monika L Metzger iD, John K Choi iD, Godwin Job, Teresa C Santiago iD, Armando Peña, Miguela A Caniza iD, Asya Agulnik iD, Pascale Y Gassant, Wendy C Gómez García iD, Patricia J Calderón, Claudia Garrido und 10 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Priya Kumar und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Burkitt Lymphoma. Die Arbeit nennt 12 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Clinical and histopathologic diagnosis of pediatric mature B-cell lymphomas (eg, Burkitt lymphoma [BL]) must be accurate to select appropriate risk-based treatment. The Central American Pediatric Hematology-Oncology Association (AHOPCA) in 2000 implemented standardized, resource-adapted treatments for these lymphomas. We evaluated the concordance of local histopathologic diagnoses through central review, determined the impact on therapy selection, and described the clinical characteristics and outcomes of pediatric patients with these lymphomas. We suggest recommendations to improve the accuracy of diagnoses. METHODS Pathology samples and reports were submitted by six AHOPCA sites to St Jude Children's Research Hospital for central review. The concordance of sample assessments was evaluated using three criteria: histologic diagnosis, morphology, and immunohistochemistry. Clinical characteristics, treatment, and outcomes were also analyzed. RESULTS Of the 68 eligible patients, 53 (78%) received an accurate pathologic diagnosis of BL. For nine (13%) patients, diagnoses changes with therapy implications were made upon central review, while in six patients, there was a minor disagreement with no therapy implications. Most (87%) patients presented with advanced disease. Detailed cellular features were absent in many reports, and immunohistochemistry was routinely performed at only one site. Of the 50 patients whose treatment data were reported, 44 (88%) completed therapy, five died during treatment, and one abandoned treatment. Treatment outcome was satisfactory: 3-year event-free survival was 74% (SE ± 11%), and overall survival was 73% (SE ± 11%). CONCLUSION Pathology laboratories in limited-resource hospitals and regions need further optimization to increase accurate diagnoses of mature B-cell lymphomas. Creating regional pathology networks will enhance diagnostic support. Despite resource limitations and advanced disease at presentation, the AHOPCA sites' adapted treatment strategies have improved patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Burkitt LymphomaHumansChildMaleFemaleChild, PreschoolAdolescentTreatment OutcomeProspective StudiesInfant

Autor:innen und Institutionen

  • Department of Pathology, St Jude Children's Research Hospital, Memphis, TN.
  • Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN.
  • Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN.
  • Médicins Sans Frontiéres, Geneva, Switzerland.
  • Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Pediatric Hematology/Oncology Service, Hospital Escuela Universitario, Tegucigalpa, Honduras.

ORCID-Profile: Monika L Metzger, John K Choi, Teresa C Santiago, Miguela A Caniza, Asya Agulnik, Wendy C Gómez García, Roy Rosado, Valentino Conter, Meenakshi Devidas, Paola Friedrich, Carlos Rodriguez Galindo, Guillermo L Chantada, Victor M Santana

Förderung

  • NCI NIH HHS

Zitieren

APA

Kumar, P., Metzger, M. L., Choi, J. K., Job, G., Santiago, T. C., Peña, A., Caniza, M. A., Agulnik, A., Gassant, P. Y., Gómez García, W. C., Calderón, P. J., Garrido, C., Rosado, R., Fuentes Alabí, S., Conter, V., Devidas, M., Carrillo, A. K., Chen, Y., Friedrich, P., …, & Santana, V. M. (2025). Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium. JCO Global Oncology. https://doi.org/10.1200/go-24-00491

Vancouver

Kumar P, Metzger ML, Choi JK, Job G, Santiago TC, Peña A, et al. Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium. JCO Global Oncology. 2025. doi:10.1200/go-24-00491

BibTeX
@article{Kumar2025,
  author = {Kumar, Priya and Metzger, Monika L and Choi, John K and Job, Godwin and Santiago, Teresa C and Peña, Armando and Caniza, Miguela A and Agulnik, Asya and Gassant, Pascale Y and Gómez García, Wendy C and Calderón, Patricia J and Garrido, Claudia and Rosado, Roy and Fuentes Alabí, Soad and Conter, Valentino and Devidas, Meenakshi and Carrillo, Angela K and Chen, Yichen and Friedrich, Paola and Rodriguez Galindo, Carlos and Chantada, Guillermo L and Santana, Victor M},
  title = {Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00491}
}
Kostenlos starten →